Failure to individualize drug dosing may waste 50% of the value of pharmaceutical innovation coming off the bench, driving the unacceptable failure rates of drug development programs and unsustainable drug costs. An immense opportunity is thus presented to investors in pharmaceutical innovation who are willing to develop and field innovative Phase 1 trial methodologies that solve this problem. The principle of Dose Titration Algorithm Tuning (DTAT) offers a reasoned strategy for accomplishing this.

Figure options

中文翻译：

---

一刀切—全剂量的肿瘤治疗浪费金钱，创新和生命

未能个性化配药可能会浪费50％的药品创新价值，从而导致药物开发计划的失败率不可接受，药物成本难以承受。因此，向愿意开发和现场解决该问题的创新性第一阶段试验方法的制药创新投资者提供了巨大的机会。剂量滴定算法调整（DTAT）的原理为实现这一目标提供了合理的策略。

图选项